Introduction
Clinical trials remain the foundation for evidence-based medicine and are essential in the evaluation of novel drug therapies and in the audit of long-term management of chronic conditions. Trials designed to evaluate anti-obesity pharmacotherapy are no exception and are conducted and constrained by guidance from regulatory authorities who seek to demonstrate efficacy and safety.
In reality, clinical trials whose purpose is to meet regulatory authorities requirements are, in many ways, artificial. In the case of obesity management, trial designs and objectives often do not translate directly into real clinical practice or address the practical clinical issues that arise when treating obesity. For example, the questions of when to start treatment and which patients to select for therapy are answered very differently for a clinical trial than they would be in clinical practice (see Table 1 ). Trials are generally conducted in a hospital setting, when in reality most obese patients present and are managed in a primary care setting.
In obesity clinical trials, patients who are unresponsive to treatment are retained for the whole duration of the trial, whereas in real life treatment would be withdrawn. This contrasts to trials of drugs developed to lower blood pressure, for example, where if a patient was found to be a treatment non-responder, they would be withdrawn both from treatment and the analysis of the mean hypotensive effect of therapy. It is necessary, of course, that studies look at weight loss maintenance over 1 -2 y periods, but including nonresponders in the statistical analysis dilutes the apparent benefit in responsive patients, since it is not possible to measure weight loss maintenance in patients who have not lost weight.
The ancillary treatment provided within the setting of a clinical trial in obesity, for example dietary advice and support in behaviour modification, is often detailed and intensive. In normal clinical practice, this intensity of support may not be readily available. Yet a further irony is that, while in clinical trials some patients may be excluded from such ancillary support because of complications of their obesity, in real practice they should and would be offered diet and behaviour modification to suit their clinical profile.
There is a dilemma, therefore, between appropriate statistical conservatism required for drug registration and everyday clinical realities and needs, which in the case of antiobesity therapies may serve to undervalue the potential of drug intervention.
Sibutramine clinical study database
A large clinical trial database for sibutramine and postmarketing surveillance data allow exploration of the factors that determine response to the drug and help to provide pointers to the clinically meaningful outcome when using this drug as part of an obesity management programme.
In all of the studies conducted with sibutramine, it is important to stress that drug treatment is accompanied by diet, ranging from a low calorie diet (LCD) to simple dietary advice, and that the 'control' subjects are also offered the same level of dietary support and exercise advice as those given drug treatment, thus the efficacy of therapy is not in the strict sense compared simply with placebo. The term control, or conventional treatment, better describes the group receiving ancillary therapy and drug placebo.
Three key long-term studies evaluating sibutramine in patients with uncomplicated obesity are described in Figure  1 . In the VLCD (very low calorie diet) study, patients underwent a run-in period on the dietary regimen before being randomised to treatment or control for a 1 y period. 1 In the STORM study, all patients began on a regimen of sibutramine plus diet and exercise for the first 6 months of the trial and were then randomised to continue with drug treatment or 'control' management alone until 24 months of study. 2 Finally, in a 1 y GP trial, there was no run-in period, with obese patients randomised into two groups -sibutramine or 'control' from the outset to study completion. 3 Two key studies in patients with type 2 diabetes have also looked at the role of sibutramine in weight management (see Figure 2 ).
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Clinically useful questions and answers
The clinically useful questions that a review of trial data and database information can help to answer are as follows. Responses after 1 y of treatment are important and studies are powered to show weight loss as a percentage reduction from initial body weight. Response rates of 5 -10% are desirable endpoints. Weight loss of 5 -10% has probable clinical benefit, weight loss > 10% has proven clinical benefit. Any weight loss (ie up to 5%), which in uncomplicated obesity might have questionable clinical value, can be of great benefit in patients with complicated disease.
Overall, the 1 y trial data 1 -5 suggest that across a variety of obesity management strategies that include sibutramine, more than two-thirds of patients achieve and maintain a > 5% weight loss, and of these, nearly half lose > 10% of initial weight.
The level of response to obesity management seen in these studies is impressive and greater than that seen with other treatment strategies for the management of obesity.
Efficacy in real clinical practice
The key question for real-world clinical practice is, can we keep patients on treatment when they are not in a clinical trial and without the intensive dietary support provided by a trial team? Evidence from a post-marketing surveillance study conducted in Germany, involving 6360 patients, would suggest that the answer to this question is 'yes'. 6 This study has found that 89% of patients remain on treatment after 3 months when managed in general practice by motivated physicians who are committed to a holistic approach to patient care and weight reduction. Steady weight loss over 12 weeks has been found in this large patient cohort, and comparison of this real-life clinical data with trial evidence shows that the same level of treatment success with sibutramine as part of obesity management can be achieved outside a trial setting (see Figure 3) .
Evidence exists, therefore, to show that real clinical practice can mirror clinical trials -after 3 months on sibutramine, more than one-third of patients can achieve a > 10% weight loss. The ongoing challenge in real practice is ensuring that this weight loss is maintained long term.
Predicting response
Clinical trials provide good indicators to which patient types and which case characteristics will predict a good response to treatment. There are age and sex differences, and initial body weight is also important for gauging likely response to a weight management programme and therapy. In general:
men seem to do less well than women in losing weight (P < 0.0001); younger patients (18 -30 y) are better at losing weight than older patients ( > 30 y) (P < 0.002) patients with an initially high body mass index (BMI) find it easier to lose weight than those with a lower BMI (P < 0.008) (see Figure 4) .
Initial weight loss in the first weeks of treatment is the most important predictor of weight loss at 1 y (see Figure 5) .
Patients with uncomplicated obesity who lose 2 kg or more at week 4 on treatment have a 73% chance of losing and maintaining > 5% body weight at 1 y, while 86% of the 5% responders had lost 2 kg or more after 4 weeks. This separation of likely responders from non-responders becomes even clearer after 3 months on therapy -if a patient has not lost 2 -3 kg by this time, their outcome at 2 -3 y is unlikely to be good in terms of percentage body weight loss.
The cut-off points for early prediction of response are very different, however, in obese patients with concomitant type 2 diabetes. These patients typically find it harder to achieve weight loss per se and in particular are slow to lose weight. Studies have shown that even patients who are not achieving 1 kg weight loss at 1 month can still enjoy clinically important weight loss after 1 y on sibutramine treatment.
Even after 3 months on therapy, an obese patient with diabetes who appears to be a slow responder, may, after 1 y, have managed good and clinically significant weight loss. For patients with type 2 diabetes, a reduction in weight of 10% or more can result in a fall in HbA 1c of 1.3%, a value that is important in achieving the diabetes management goal of improved glycaemic control.
In real clinical practice, therefore, the weight loss seen at 1 month and 3 months can be helpful in determining which patients are going to succeed on a programme involving sibutramine therapy. If a patient has type 2 diabetes, however, it is expected that weight loss in the early months will be slow and the same predictive value should not be placed on progress at 1 month as would be given to non-diabetic overweight patients.
Other complicating factors
In real clinical practice, the overweight patient population includes large numbers of patients with coexisting diseases. Patients with type 2 diabetes present particular management challenges, because it is known that weight loss in this population is a key management goal, conferring important clinical benefits. Other metabolic disorders, such as dyslipidaemia and coexisting hypertension, are common in the overweight. Like diabetes, these conditions and risk factors are known to improve with weight loss, and in these patient populations, even modest and slow progress in achieving weight reduction can have major clinical benefits. The presence of comorbidities affects the likelihood of good weight loss, as shown in Figure 6 .
Quality of life data
Four studies conducted in the USA in which daily sibutramine treatment, 20 mg=day for complicated obesity, was used as part of an obesity management programme, looked at aspects of patients' quality of life before and after weight loss. 7 Using recognised and validated quality of life rating scales, it was found that patients reported a gradual and real change in their daily physical activities and quality of life that correlated with sibutramine-induced weight loss. Patients reported improvements in mobility, better physical function, reduced pain, and higher levels of activity as they lost body weight. When questioned about the emotional aspects of their improved quality of life, after 6 -12 months on therapy, improvements were seen in patient self-esteem, general vitality and feeling of health; emotional well-being also improved and patients felt more sociable.
The emotional benefits of weight loss seem particularly marked during the early stages of weight loss, and tend to lessen with time, despite the fact that physical weight loss is maintained in most cases. A key task for those involved in the management of overweight patients in real clinical practice, therefore, will be to support patients through the various stages of weight loss that are achievable with sibutramine, helping individuals to maintain their positive feelings about weight loss.
Summary
Clinical trial data and evidence from clinical practice show that sibutramine is a valuable adjunct to weight reduction programmes that involve diet and exercise alone. Over twothirds of patients can achieve a > 5% weight loss, and the clinical benefits of this are marked for all patients. Weight loss at 1 month is a good predictor of weight loss at 1 y in patients with uncomplicated obesity, but for those with diabetes, a slower progress need not indicate early signs of treatment failure. Patients with complicated obesity are often slower to respond and may achieve slightly less weight loss than those who are otherwise healthy, but the benefits of weight loss in these groups can be important. Weight loss is accompanied by improvements in both physical and emotional well-being. Medical support and management on a long-term basis can help with patient compliance and treatment success, and all the pointers suggest that the excellent results seen with sibutramine in clinical trials can be achieved and mirrored in everyday clinical practice. 
